Regeneron Pharmaceuticals Inc's COVID-19 antibody therapy has been accorded the emergency use authorisation by the United States (US)' Food and Drug Administration (FDA), Livemint.
The monoclonal antibody therapy involves the administration of two antibodies called casirivimab and imdevimab together and helps treat mild to moderate cases of COVID-19 in adults and pediatric patients who have either tested positive for the disease or are at the high risk of progressing to a severe state.
The clinical trial of the therapy showed that it was able to reduce the COVID-19-related hospitalisation or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo.
The move to authorise the therapy's emergency use is likely to help the outpatients avoid hospitalisation and alleviate the burden on the health care system.
It should be noted that when President Donald Trump had tested positive for COVID-19, he too had been given an experimental treatment of the therapy which he said helped cure him of the disease.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 999/year is the best way you can support our efforts.